KRAS inhibitor-10
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1[1].
Product Specifications
CAS Number
[2578876-75-0]
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kras-inhibitor-10.html
Concentration
10mM
Purity
99.92
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1C(C2=CC=C(OC)C=C2C)C3=C(C=C(OC)C(OCCC4=CC=C(OC)C(N)=C4)=C3)CC1)NCC
Molecular Formula
C30H37N3O5
Molecular Weight
519.63
References & Citations
[1]Miguel VEGA GARCÍA, et al. Tetrahydroisoquinoline compounds. Patent wo2021002165
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
K-Ras
Available Sizes
Explore Other Products
Browse additional items from our catalog
Rabbit Polyclonal Calcium Activated Nucleotidase 1/CANT1 Antibody
MuSK, CT (Muscle Skeletal Receptor Tyrosine Kinase, MGC126323, MGC126324, Muscle Specific Kinase Receptor, Muscle Specific Tyrosine Protein Kinase Receptor, Receptor Tyrosine Kinase MuSK, Skeletal Muscle Receptor Tyrosine Kinase) (MaxLight 750) discontinued
